Department of Drug Administration orders recall of Pantoloc from the market

Nepal Health News, Kathmandu – The Department of Drug Administration (DDA) has ordered the recall of a medicine from the market, citing quality concerns. The directive was issued after the drug failed quality control tests conducted at the department's laboratory. As a result, the sale, distribution, and use of the medicine have been immediately halted.

The medicine in question is Pantoloc (Pantoprazole Tablets IP) with batch number TPT-129 (B). According to the department, the drug failed the Dissolution Test (Buffer Stage), and was therefore deemed substandard, prompting the recall order.

The department has reported that this particular batch was manufactured in December 2024 and is set to expire in November 2027.

All concerned parties have been instructed not to sell, distribute, or use the medicine. Additionally, the general public has been advised to exercise caution regarding the use of this drug.